Nrf2/Bach1 signaling axis: A promising multifaceted therapeutic strategy for Alzheimer's disease
Authors:
- Andrew A. PieperAPAndrew A. Pieper
- Bobby ThomasBobby Thomas
Open Access
- 8 April 2025
- journal article
- review article
- Published by Elsevier in Neurotherapeutics
- Vol. 22 (3) , e00586
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01NS133688)
- US Department of Defense (P01CA203653, R01AG071512, HT94252310443)
- Case Western Reserve University
- Johns Hopkins University
This publication has 118 references indexed in Scilit:
- 2024 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2024
- Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseasesArchives of Toxicology, 2024
- Emerging small molecule inhibitors of Bach1 as therapeutic agents: Rationale, recent advances, and future perspectivesBioEssays, 2023
- ROS-induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosisArchives of Toxicology, 2023
- Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer DiseaseJAMA Neurology, 2022
- Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer DiseaseJAMA Neurology, 2022
- Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer DiseaseJAMA Neurology, 2020
- NF‐E2‐related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilin‐1 mutated Alzheimer's disease astrocytesGlia, 2019
- Oxidative stress in Alzheimer disease and mild cognitive impairment: evidence from human data provided by redox proteomicsArchives of Toxicology, 2015
- Aberrant protein expression of transcription factors BACH1 and ERG, both encoded on chromosome 21, in brains of patients with Down syndrome and Alzheimer’s disease2003